Obesity Clinical Trial
— MBSR&TREOfficial title:
Feasibility and Acceptability of a Remote Time-Restricted Eating and Mindfulness-Based Stress Reduction Intervention to Reduce Risk Factors Associated With Early-Onset Colorectal Cancer Development Among Young Adults
The goal of this clinical trial is to evaluate the feasibility of remote time-restricted eating (TRE) and mindfulness-based stress reduction (MBSR) interventions and the preliminary effect on EOCRC-related markers. The main question[s] it aims to answer are: - Is it feasible and acceptable to conduct 8-week remote interventions of TRE, MBSR, and combined TRE+MBSR among young adults with excess adiposity and moderate-to-severe perceived stress? - Will participants in the combined group lose more body weight and reduce their stress levels than those in the remaining groups? - Will participants in the combined group experience better body composition changes and improve their cardiometabolic health compared to those in the remaining groups? - Will participants in the combined group exhibit changes in the microbiome compared to those in the remaining groups? Participants will: - Complete 8 weeks of a TRE intervention - Complete 8 weeks of a remote MBSR intervention Researchers will compare 1. TRE alone; 2. MBSR alone; 3. TRE + MBSR; and 4. Control to see if the study is feasible and acceptable; to see if individuals lose body weight; to see if individual stress levels reduce; to see changes in the microbiome.
Status | Recruiting |
Enrollment | 48 |
Est. completion date | May 2024 |
Est. primary completion date | May 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 39 Years |
Eligibility | Inclusion Criteria: 1. 18-39 years old. 2. BMI 30-49.99 kg/m2. 3. Own and use a smartphone, computer, or tablet with access to the Internet. 4. Score = 14 on the Perceived Stress Score (PSS) at screening. Exclusion Criteria: 1. Have a personal or family history of EOCRC. 2. Have taken antibiotics in the previous 2 months. 3. Have an inflammatory bowel disease or genetic predisposition to EOCRC or CRC (e.g., Lynch syndrome);. 4. Any cancer diagnosis or cancer treatment in the past 12 months. 5. Consume >50 grams ethanol daily (approximately 4-5, 12 ounces beers). 6. Use combustible tobacco. 7. Have history of bariatric surgery or bowel resection. 8. Have an active infection. 9. Have type 1 or type 2 diabetes, immunodeficiency/autoimmune disorder, or inflammatory bowel disease. 10. Use fiber or pre-/probiotic supplements >3 days per week. 11. Currently taking corticosteroids medication - inhaled, topical, or oral in the past 2 months (affects cortisol measures). 12. Are on a weight-loss diet or involved in a formal weight-loss program or are not weight stable for 3 months (+/- 4.5 kg) prior to the study. 13. Females who are pregnant/trying to become pregnant. 14. Have schizophrenia (medication can affect study outcomes). 15. Have an eating window of <10 hours/day or are currently following an intermittent fasting pattern. 16. Night shift workers (shift passes midnight). 17. Present a history of eating disorder. 18. Currently taking weight loss medication. 19. Illegal drug use in the past month (not marijuana). |
Country | Name | City | State |
---|---|---|---|
United States | Applied Health Sciences Building - University of Illinois at Chicago | Chicago | Illinois |
Lead Sponsor | Collaborator |
---|---|
Lisa Tussing-Humphreys | University of Illinois at Chicago |
United States,
Doubeni CA, Major JM, Laiyemo AO, Schootman M, Zauber AG, Hollenbeck AR, Sinha R, Allison J. Contribution of behavioral risk factors and obesity to socioeconomic differences in colorectal cancer incidence. J Natl Cancer Inst. 2012 Sep 19;104(18):1353-62. doi: 10.1093/jnci/djs346. Epub 2012 Sep 5. — View Citation
Sinicrope FA. Increasing Incidence of Early-Onset Colorectal Cancer. N Engl J Med. 2022 Apr 21;386(16):1547-1558. doi: 10.1056/NEJMra2200869. No abstract available. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Feasibility of the study | the number of people interested in the study, those who pass phone and in-person screenings, and those who decline enrollment and their reasons. Once enrolled, we will closely monitor attendance, data completeness, session attendance, asynchronous intervention usage, and loss to follow-up/withdrawal. To monitor participant progress, we will update the CONSORT participant flow diagram every week. Participants who withdraw voluntarily will be asked for their reasons. | Baseline; through study completion, an average of 9 weeks | |
Primary | Acceptability of the study | Participants will complete the acceptability of intervention measure (scores range from 4-20 points with higher scores reflecting higher acceptability). | Week 4 of the intervention; through study completion, an average of 9 weeks | |
Secondary | Hair cortisol | Objective stress markers will be measured via hair cortisol | Baseline; through study completion, an average of 9 weeks | |
Secondary | Serum adrenocorticotropic hormone (ACTH) | Objective stress markers will be measured via serum ACTH. | Baseline; through study completion, an average of 9 weeks | |
Secondary | Serum cortisol | Objective stress markers will be measured via serum cortisol. | Baseline; through study completion, an average of 9 weeks | |
Secondary | Serum norepinephrine | Objective stress markers will be measured via serum norepinephrine | Baseline; through study completion, an average of 9 weeks | |
Secondary | Perceived Stress Scale. | The Perceived Stress Scale queries participants' perceptions of feeling stress during the last month. Responses were on a 5-point scale from "never" to "very often." Scores will be summed to indicate current stress levels, with higher scores suggesting greater perceived stress (= 14 indicates moderate to high perceived stress). | Screening; through study completion, an average of 9 weeks | |
Secondary | Body fat mass | Body fat mass will be measured via whole body dual energy x-ray absorptiometry (DEXA) scan. | Baseline; through study completion, an average of 9 weeks | |
Secondary | Body lean mass | Body lean mass will be measured via whole body dual energy x-ray absorptiometry (DEXA) scan. | Baseline; through study completion, an average of 9 weeks | |
Secondary | Body bone density | Body bone density will be measured via whole body dual energy x-ray absorptiometry (DEXA) scan. | Baseline; through study completion, an average of 9 weeks | |
Secondary | Triglycerides | Will be measured from plasma by a commercial lab. | Baseline; through study completion, an average of 9 weeks | |
Secondary | High sensitivity C-reactive protein. | Will be measured from plasma by a commercial lab. | Baseline; through study completion, an average of 9 weeks | |
Secondary | homeostasis model assessment-insulin resistance (HOMA-IR) | calculated from fasting glucose and insulin using a standard formula. | Baseline; through study completion, an average of 9 weeks | |
Secondary | Microbial Deoxyribonucleic acid (DNA) isolation: 16S on V4 region | performed on stool using Microbial DNA isolation | Baseline; through study completion, an average of 9 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |